Which Nutrients Are GLP-1 Users Actually Falling Short On? What 2026 Research Shows
FAQ-000051
Direct Answer
A 2026 systematic review in Clinical Obesity, covering six studies and nearly 481,000 adults, found that micronutrient deficiencies during GLP-1 therapy are a common consequence of treatment, not a rare adverse effect. Vitamin D deficiency was the most frequently diagnosed issue, found in 7.5% of users at 6 months and 13.6% at 12 months. Iron depletion was also frequent, with GLP-1 users showing 26 to 30% lower ferritin levels than people on a different diabetes medication class (SGLT2 inhibitors). More than 60% of users consumed below recommended levels of calcium and iron, and average vitamin D intake reached only about 20% of recommendations.
Why This Happens
Current evidence suggests GLP-1 medications don't directly impair how the intestines absorb nutrients. The mechanism appears to be more straightforward: reduced overall food intake, driven by appetite suppression and slowed gastric emptying, naturally reduces micronutrient intake alongside calorie intake, particularly when food variety narrows during treatment. Rapid weight loss itself also affects how the body stores and mobilizes certain vitamins, and accelerated bone remodeling during weight loss can specifically affect calcium and vitamin D levels.
The Nutrients With the Strongest Evidence Behind Them
According to a February 2026 review specifically ranking the strength of evidence, iron and vitamin D currently show the strongest documented signals, followed by vitamin B12, calcium, magnesium, potassium, and zinc. A separate claims-based cohort found GLP-1 users had a 49% higher risk of vitamin D deficiency compared to SGLT2 inhibitor users, and 32% higher risk compared to DPP-4 inhibitor users, real comparative numbers, not just an isolated finding.
A Serious Finding Worth Knowing About
Separate case reports have linked GLP-1 use to severe thiamine (vitamin B1) deficiency, including documented cases of Wernicke encephalopathy and beriberi, both serious neurological conditions. The researchers behind this specific finding noted that unexplained neurologic symptoms, gait disturbances, or cognitive changes in someone on a GLP-1 medication, particularly during a period of significant caloric restriction, warrant prompt medical evaluation rather than being assumed to be an unrelated issue. This is genuinely rare, but the consequences of missing it can be serious and are not always fully reversible, which is why it's worth knowing about even though it affects a small minority of patients.
What This Means Practically
This isn't a reason to avoid GLP-1 treatment, it's a reason to be proactive about nutrition rather than assume appetite suppression is only affecting calorie count. Prioritizing protein, calcium, and vitamin D intake specifically, discussed in more detail on our Protein and Vitamins pages, and discussing baseline and periodic lab monitoring with your provider, particularly if you're experiencing persistent low appetite, vomiting, or significant caloric restriction, are reasonable, evidence-supported steps.
References
- Urbina et al., Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy, A Narrative Review, Clinical Obesity (January 2026)
- Micronutrient Risk with GLP-1 Receptor and Dual Incretin Agonists in Obesity, A Monitoring Framework, ScienceDirect (2026)
- Medscape: What Nutrients Are GLP-1 Users Lacking? (February 2026)
Related Resources
- The ADA's 2026 Standards of Care Now Formally Recommends Nutrition Monitoring on GLP-1 Therapy
- Vitamins and Supplements to Consider on a GLP-1 Medication
- Protein
- Why Your GLP-1 Provider Wants to See Your Nutrition Data, Not Just Your Dose History
Related Articles
Explore More
Explore the full GLP-1 Tracker knowledge base on DietApp.com
Get Started
Explore the GLP-1 Tracker knowledge base to track your nutrition alongside your medication.
About DietApp.com
DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This article is for general informational purposes and does not constitute medical advice. If you experience unexplained neurological symptoms, confusion, gait changes, or significant weakness while on a GLP-1 medication, seek prompt medical evaluation.
glp-1-nutrient-deficiencies-research